MX2011013722A - Formulaciones liofilizadas para inmunofarmaceuticos modulares pequeños. - Google Patents

Formulaciones liofilizadas para inmunofarmaceuticos modulares pequeños.

Info

Publication number
MX2011013722A
MX2011013722A MX2011013722A MX2011013722A MX2011013722A MX 2011013722 A MX2011013722 A MX 2011013722A MX 2011013722 A MX2011013722 A MX 2011013722A MX 2011013722 A MX2011013722 A MX 2011013722A MX 2011013722 A MX2011013722 A MX 2011013722A
Authority
MX
Mexico
Prior art keywords
small modular
provides
present
lyophilized formulations
formulations
Prior art date
Application number
MX2011013722A
Other languages
English (en)
Inventor
Li Li
Angela Kantor
Nicholas Luksha
Nicholas WARNE
Serguei Tchessalov
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of MX2011013722A publication Critical patent/MX2011013722A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención proporciona, entre otras cosas, formulaciones estables para proteínas inmunofarmacéuticas modulares pequeñas (SMIPTM). En ciertas modalidades, la presente invención proporciona una formulación que contiene una mezcla liofilizada de una proteína inmunofarmacéutica modular pequeña, en donde menos de 7% de la proteína inmunofarmacéutica modular pequeña liofilizada existe en forma agregada. Las formulaciones de acuerdo con la invención pueden contener agentes reguladores, estabilizadores, agente espesantes, agentes tensioactivos y/u otros excipientes. La presente invención proporciona también formulaciones para liofilización, reconstitución y métodos de uso.
MX2011013722A 2009-06-18 2010-06-18 Formulaciones liofilizadas para inmunofarmaceuticos modulares pequeños. MX2011013722A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21838809P 2009-06-18 2009-06-18
US21838609P 2009-06-18 2009-06-18
PCT/US2010/039227 WO2010148337A1 (en) 2009-06-18 2010-06-18 Lyophilized formulations for small modular immunopharmaceuticals

Publications (1)

Publication Number Publication Date
MX2011013722A true MX2011013722A (es) 2012-05-08

Family

ID=43356778

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011013722A MX2011013722A (es) 2009-06-18 2010-06-18 Formulaciones liofilizadas para inmunofarmaceuticos modulares pequeños.

Country Status (11)

Country Link
US (1) US20120114646A1 (es)
EP (1) EP2442798A4 (es)
JP (1) JP2012530721A (es)
KR (1) KR20120027031A (es)
CN (1) CN102695499A (es)
AU (1) AU2010263058A1 (es)
CA (1) CA2764180A1 (es)
IL (1) IL217065A0 (es)
MX (1) MX2011013722A (es)
RU (1) RU2011151286A (es)
WO (1) WO2010148337A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3424529A1 (en) 2007-07-02 2019-01-09 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
CA2976671C (en) 2010-03-01 2021-01-12 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
AR084938A1 (es) 2011-01-28 2013-07-10 Sanofi Sa Anticuerpos humanos contra la proproteina convertasa subtilisina/kexina tipo 9 (anti pcsk9) para usar en metodos para tratar grupos de pacientes
KR102050339B1 (ko) 2011-03-15 2019-11-29 바이오젠 엠에이 인코포레이티드 빠른 적정 단계식 증가 투여 요법을 이용한 인터페론의 근육내 투여와 관련된 독감 유사 증상의 감소 방법
US8802097B2 (en) 2011-07-15 2014-08-12 Oncomed Pharmaceuticals, Inc. Anti-RSPO1 antibodies
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
ES2369945B1 (es) * 2011-07-29 2012-10-15 Eduardo Anitua Aldecoa Procedimiento de obtención de una composición que contiene factores de crecimiento a partir de un compuesto sanguíneo, y composición obtenible por dicho procedimiento.
AU2012308797B2 (en) 2011-09-16 2017-06-01 Regeneron Pharmaceuticals, Inc. Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PSCK9)
MX2015000565A (es) 2012-07-13 2015-04-10 Oncomed Pharm Inc Agentes de union de proteina de r-espondina humana (rspo3) y usos de los mismos.
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
PL2916866T3 (pl) 2012-11-06 2018-10-31 Bayer Pharma Aktiengesellschaft Formulacja dwuswoistych przeciwciał mobilizujących limfocyty t (bite)
US11576863B2 (en) 2013-03-15 2023-02-14 Takeda Pharmaceutical Company Limited Formulation of an antibody and use thereof
UY35463A (es) 2013-03-15 2014-10-31 Biogen Idec Inc Formulaciones de polipéptido fc-factor ix.
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
KR20160024906A (ko) 2013-06-07 2016-03-07 사노피 바이오테크놀로지 Ｐｃｓｋ9의 억제제를 투여함에 의한 죽상경화증의 억제 방법
EP3882273A1 (en) 2013-11-12 2021-09-22 Sanofi Biotechnology Dosing regimens for use with pcsk9 inhibitors
WO2015076285A1 (ja) * 2013-11-21 2015-05-28 協和メデックス株式会社 血清又は血漿中の低密度リポ蛋白の凍結乾燥による変性抑制剤及び変性抑制方法
KR102385372B1 (ko) 2014-03-24 2022-04-11 바이오버라티브 테라퓨틱스 인크. 동결건조된 ix 인자 제형
US9937239B2 (en) 2014-05-21 2018-04-10 The Johns Hopkins University Preservation and reconstitution of cell-free protein expression systems
US20170209582A1 (en) * 2014-06-26 2017-07-27 Amgen Inc. Protein formulations
KR20170029613A (ko) 2014-07-16 2017-03-15 사노피 바이오테크놀로지 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
AU2015301538A1 (en) * 2014-08-15 2017-03-02 Oncomed Pharmaceuticals, Inc. RSPO1 binding agents and uses thereof
US10064937B2 (en) 2014-09-16 2018-09-04 Oncomed Pharmaceuticals, Inc. Treatment of dermal fibrosis
EP3337828A1 (en) 2015-08-18 2018-06-27 Regeneron Pharmaceuticals, Inc. Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis
RU2751235C2 (ru) * 2016-02-24 2021-07-12 Байомарин Фармасьютикал Инк. Терапевтические слитые белки направленного действия на основе лизосомных ферментов, соответствующие составы и их применения
GB201608323D0 (en) * 2016-05-12 2016-06-29 Ucb Biopharma Sprl Pharmaceutical compositions
CA3032596A1 (en) 2016-08-29 2018-03-08 Tiziana Life Sciences Plc Anti-cd3 antibody formulations
MY197672A (en) * 2016-10-07 2023-07-03 Regeneron Pharma Room temperature stable lyophilized protein
CN107088224B (zh) * 2017-02-10 2020-06-26 温州医科大学 人fgf21冻干制剂
SG11201910134SA (en) * 2017-05-02 2019-11-28 Merck Sharp & Dohme Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
EP4364724A2 (en) 2018-05-10 2024-05-08 Regeneron Pharmaceuticals, Inc. High concentration vegf receptor fusion protein containing formulations
UY38238A (es) * 2018-05-25 2019-12-31 Genzyme Corp Composiciones farmacéuticas para el tratamiento de la deficiencia de esfingomielinasa ácida
KR102646145B1 (ko) 2018-05-31 2024-03-11 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 모공 축소용 조성물
JP7079984B2 (ja) 2018-07-28 2022-06-03 エクソコバイオ インコーポレイテッド エキソソームの凍結乾燥方法
KR102163806B1 (ko) 2018-07-30 2020-10-07 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 피지분비 감소용 조성물
US20210079111A1 (en) * 2018-08-04 2021-03-18 AbCyte Therapeutics Inc. Cd19-cd20 bispecific and dual passway car-t and methods for use thereof
MA55033A (fr) 2019-02-18 2021-12-29 Lilly Co Eli Formulation d'anticorps thérapeutique
IL308881A (en) * 2021-05-28 2024-01-01 Xyone Therapeutics Inc Multispecific antibody constructs against THEMUC1-C/extracellular domain (MUC1-C/ECD)
CN116479088A (zh) * 2022-11-15 2023-07-25 江苏默乐生物科技股份有限公司 一种生物试剂冻干保存的试剂组合、试剂盒、方法及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
ATE220558T1 (de) * 1997-11-22 2002-08-15 Roche Diagnostics Gmbh Verbessertes verfahren zur stabilisierung von proteinen
BRPI0618893A2 (pt) * 2005-11-22 2011-09-13 Wyeth Corp formulações de proteìna de fusão de imunoglobulina
AU2008232902B2 (en) * 2007-03-30 2013-10-03 Medlmmune, Llc Antibody formulation
US20090208492A1 (en) * 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
WO2009158529A2 (en) * 2008-06-26 2009-12-30 Straher, Michael, P. Lyophilization cycle robustness strategy

Also Published As

Publication number Publication date
KR20120027031A (ko) 2012-03-20
US20120114646A1 (en) 2012-05-10
EP2442798A4 (en) 2013-03-13
CN102695499A (zh) 2012-09-26
EP2442798A1 (en) 2012-04-25
JP2012530721A (ja) 2012-12-06
RU2011151286A (ru) 2013-07-27
WO2010148337A1 (en) 2010-12-23
AU2010263058A1 (en) 2012-01-12
CA2764180A1 (en) 2010-12-23
IL217065A0 (en) 2012-02-29

Similar Documents

Publication Publication Date Title
MX2011013722A (es) Formulaciones liofilizadas para inmunofarmaceuticos modulares pequeños.
SG144075A1 (en) Protein stabilization formulations
MX2012002861A (es) Formulaciones farmaceuticas muy concentradas.
AU2016204371A1 (en) Lyophilised and aqueous anti-CD40 antibody formulations
MX2009010179A (es) Formulaciones estables de anticuerpo.
NZ603813A (en) Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-trna synthetases
EA201490804A1 (ru) Препараты этанерцепта, стабилизированные хлоридом натрия
PH12015500773B1 (en) Methods and compositions for live attenuated viruses
WO2010100200A3 (en) Lyophilised antibody formulation
MY159464A (en) Reconstituted surfactant composition containing analogs of surfactant protein b (sp-b) and surfactant protein c (sp-c)
NZ602685A (en) Concentrated protein formulations and uses thereof
GEP20125628B (en) Pharmaceutical compositions containing antagonist anti-cd40 antibody
IN2012DN00801A (es)
MX2010002002A (es) Peptido foxm1 y agente medicinal que lo contiene.
MX2010002001A (es) Peptido cdca1 y agente farmaceutico que comprende elmismo.
NZ605873A (en) Methods and compositions for cns delivery of arylsulfatase a
MX2010002018A (es) Peptido de cdh3 y agente medicinal que comprende al mismo.
JO2963B1 (en) Reconstructed surfactants with improved properties
EA200970981A1 (ru) Пептидная смесь в качестве стабилизатора вина
SG10201407944TA (en) Imp-3 oligopeptides and vaccines including the same
NZ631131A (en) Reconstituted hdl formulation
MX2021012939A (es) Formulaciones de factor ix liofilizadas.
CY1115938T1 (el) Νεα συνθεση για αυξηση της bio-διαθεσιμοτητας της νεουρτουρινης (neurturin)
WO2008063865A3 (en) Biphosphonate inhalant formulations and methods for using the same
EA201490363A1 (ru) Новые составы на основе (триметоксифениламино)пиримидинилов

Legal Events

Date Code Title Description
FA Abandonment or withdrawal